Analysts Set Entellus Medical, Inc. (NASDAQ:ENTL) Price Target at $21.25

Shares of Entellus Medical, Inc. (NASDAQ:ENTL) have earned a consensus rating of “Hold” from the ten ratings firms that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $21.25.

A number of analysts have recently weighed in on the company. BidaskClub cut Entellus Medical from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Piper Jaffray Companies reissued a “buy” rating on shares of Entellus Medical in a research report on Wednesday, July 12th. Zacks Investment Research raised Entellus Medical from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. William Blair reaffirmed an “outperform” rating on shares of Entellus Medical in a research report on Wednesday, May 10th. Finally, ValuEngine raised Entellus Medical from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd.

TRADEMARK VIOLATION WARNING: This news story was published by [[site]] and is owned by of [[site]]. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at [[permalink]].

Entellus Medical (ENTL) remained flat at $17.10 on Friday. The company’s stock had a trading volume of 167,340 shares. Entellus Medical has a 12-month low of $11.47 and a 12-month high of $22.63. The stock’s market capitalization is $433.84 million. The stock has a 50-day moving average of $16.88 and a 200-day moving average of $14.99.

Entellus Medical (NASDAQ:ENTL) last posted its quarterly earnings data on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.03. The business had revenue of $22.10 million during the quarter, compared to analyst estimates of $21.87 million. Entellus Medical had a negative return on equity of 60.34% and a negative net margin of 41.11%. The firm’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.27) EPS. Equities research analysts anticipate that Entellus Medical will post ($1.62) earnings per share for the current year.

Several institutional investors have recently added to or reduced their stakes in ENTL. Frontier Capital Management Co. LLC bought a new position in Entellus Medical during the first quarter worth $6,464,000. William Blair Investment Management LLC raised its position in Entellus Medical by 1,017.0% in the first quarter. William Blair Investment Management LLC now owns 390,334 shares of the medical technology company’s stock worth $5,387,000 after buying an additional 355,388 shares during the last quarter. Nicholas Company Inc. raised its position in Entellus Medical by 1,052.3% in the second quarter. Nicholas Company Inc. now owns 247,685 shares of the medical technology company’s stock worth $4,101,000 after buying an additional 226,190 shares during the last quarter. Kingdon Capital Management L.L.C. raised its position in Entellus Medical by 79.6% in the first quarter. Kingdon Capital Management L.L.C. now owns 450,371 shares of the medical technology company’s stock worth $6,215,000 after buying an additional 199,615 shares during the last quarter. Finally, Grandeur Peak Global Advisors LLC raised its position in Entellus Medical by 868.1% in the first quarter. Grandeur Peak Global Advisors LLC now owns 212,491 shares of the medical technology company’s stock worth $2,932,000 after buying an additional 190,541 shares during the last quarter. Institutional investors and hedge funds own 76.84% of the company’s stock.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.